MISSISSAUGA, ON, Sept. 4, 2014 /CNW/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that John London, the Company's President and Co-Chief Executive Officer will be providing a corporate update at the Rodman & Renshaw Global Investment Conference on Tuesday, September 9, 2014 in New York.
A copy of the presentation will be available on the Company's website at www.nuvoresearch.com.
About Nuvo Research Inc.
Nuvo (TSX:NRI) is a specialty pharmaceutical company with a diverse portfolio of products and technologies. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group has four U.S. Food and Drug Administration (FDA) approved commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and four drug delivery platforms that support the development of patented formulations that can deliver actives into or through the skin. The Immunology Group has two commercial products, a development program for the treatment of allergic rhinitis and an immune system modulation platform that has the potential to support treatments for a broad range of immune system related disorders. For additional company information visit www.nuvoresearch.com.
SOURCE: Nuvo Research Inc.
For further information: Investor Relations, Email: email@example.com